Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Understanding adherence to HIV medication.
Leider JM, Kalkut G. Leider JM, et al. Ann Intern Med. 2000 Mar 7;132(5):418. doi: 10.7326/0003-4819-132-5-200003070-00018. Ann Intern Med. 2000. PMID: 10691599 No abstract available.
Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065).
El-Sadr WM, Donnell D, Beauchamp G, Hall HI, Torian LV, Zingman B, Lum G, Kharfen M, Elion R, Leider J, Gordin FM, Elharrar V, Burns D, Zerbe A, Gamble T, Branson B; HPTN 065 Study Team. El-Sadr WM, et al. JAMA Intern Med. 2017 Aug 1;177(8):1083-1092. doi: 10.1001/jamainternmed.2017.2158. JAMA Intern Med. 2017. PMID: 28628702 Free PMC article. Clinical Trial.
Barriers and facilitators of linkage to HIV primary care in New York City.
Bauman LJ, Braunstein S, Calderon Y, Chhabra R, Cutler B, Leider J, Rivera A, Sclafane J, Tsoi B, Watnick D. Bauman LJ, et al. J Acquir Immune Defic Syndr. 2013 Nov 1;64 Suppl 1(0 1):S20-6. doi: 10.1097/QAI.0b013e3182a99c19. J Acquir Immune Defic Syndr. 2013. PMID: 24126445 Free PMC article.
Design of the HPTN 065 (TLC-Plus) study: A study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States.
Gamble T, Branson B, Donnell D, Hall HI, King G, Cutler B, Hader S, Burns D, Leider J, Wood AF, G Volpp K, Buchacz K, El-Sadr WM; HPTN 065 Study Team. Gamble T, et al. Clin Trials. 2017 Aug;14(4):322-332. doi: 10.1177/1740774517711682. Epub 2017 Jun 19. Clin Trials. 2017. PMID: 28627929 Free PMC article. Clinical Trial.
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Fätkenheuer G, et al. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. N Engl J Med. 2008. PMID: 18832245 Free article.
43 results